Firstly described in 1992, the receptor for advanced glycation end-products has attracted
increasing attention due to its diverse ligand repertoire and involvement in several
pathophysiological processes associated with inflammation such as in diabetes, cancer,
autoimmune diseases and neurodegenerative diseases. This receptor in addition to its
binding capacity for advanced glycation end-products also recognizes some molecules
classified as both, pathogen-and damage-associated molecular patterns and thus triggering …